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Background Right heart thrombus (RHTh) complicated by pulmonary embolism (PE) usually presents as a medical emergency
with significant haemodynamic instability. However, less is known about subacute presentations.
...................................................................................................................................................................................................
Case summary We present a 74-year-old haemodynamically stable gentleman with a 3-week history of mild pleuritic chest pain
and exertional dyspnoea preceded by lower respiratory tract infection. Early trans-thoracic echocardiogram (TTE)
revealed a 3 cm elongated tricuspid valve thrombus with right ventricular dysfunction, new-onset atrial fibrillation,
and new-onset severe left ventricular impairment. Subsequent computed tomography pulmonary angiogram
showed widespread bilateral pulmonary emboli with retrograde opacification of the hepatic veins. The RHTh suc-
cessfully resolved with warfarin therapy with no further complications, and the patient was discharged on Day 8 of
hospitalization.
...................................................................................................................................................................................................
Discussion An early TTE is crucial in detecting the RHTh in patients suspected of PE and can significantly change the manage-
ment compared with uncomplicated PE. The index of suspicion for PE and RHTh should remain high even in sub-
acute cases.
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Learning points
• Right heart thrombus (RHTh) carries a worse prognosis and is an important differential diagnosis in patients suspected of pulmonary
embolism (PE).
• Early trans-thoracic echocardiogram in patients suspected of PE is crucial in ruling out RHTh and can alter the management early.
• Recognition of trigger and prothrombotic factors are important as they have an impact on the duration of anticoagulation of this high-risk
pathology.
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Right heart thrombus (RHTh) is an infrequent finding in the presence
of pulmonary embolism (PE) and has higher mortality than PE alone.1,2
Two types of RHTh are commonly described. First, type A, highly mo-
bile and serpiginous thrombi, usually arise from the peripheral venous
system and are thought to be incidentally caught-in-transit in the right
heart chambers.3 Second, type B thrombi are less mobile, attached to
the cardiac walls, and with morphology similar to that of left ventricular
thrombi.4 They are thought to form in situ secondary to atrial fibrillation
(AF), intracardiac abnormalities or devices, and prosthetic valves.3
Currently, no guidelines on the optimal treatment of RHTh are
available due to the lack of randomized clinical trials. Cases of RHTh
in the presence of PE are commonly reported in an emergency set-
ting and are treated with either anticoagulation, thrombolysis, sur-
gery, or percutaneous removal.5 We present a case of subacute
bilateral pulmonary emboli and concurrent type A RHTh in a patient
with new-onset AF and left ventricular (LV) dysfunction, who was
successfully treated with oral anticoagulation therapy.
Timeline
Case presentation
A 74-year-old Caucasian male presented to the emergency depart-
ment with a 1-month history of mild pleuritic chest pain, exertional
dyspnoea, orthopnoea, and productive cough unresponsive to anti-
biotic therapy. His medical history was notable for chronic kidney dis-
ease, hypertension, and ischaemic heart disease. His regular
medications on admission included bisoprolol 5 mg once daily, ator-
vastatin 40 mg once daily, lercanidipine 20 mg once daily, losartan
50 mg once daily, and aspirin 75 mg once daily. The patient was
haemodynamically stable with a heart rate of 90 b.p.m. and blood
pressure of 129/103 mmHg. His temperature was 35.8C, and the re-
spiratory rate was 19 breaths per minute with oxygen saturation of
94% on room air. Cardiovascular examination was remarkable for an
irregular pulse and mild bilateral lower limb oedema, with no clinical
evidence of deep venous thrombosis. An electrocardiogram (ECG)
showed new-onset AF with a ventricular response of 95 b.p.m., with
inferior and anterior T-wave inversions, indicating right heart strain
(Figure 1).
Blood results were: haemoglobin 153 g/L (130–170 g/L), white cell
count 9.4  109/L (4–9  109/L), C-reactive protein 20 mg/L (0–
5 mg/L), eGFR 34 mL/min (baseline: 48 mL/min), creatinine 175mmol/
L (59–104mmol/L), serial troponin T: 58–46 ng/L (0–14 ng/L). Chest
X-ray was normal. Blood cultures remained negative for 7 days. An
early point-of-care ultrasound performed in the emergency depart-
ment demonstrated a right ventricular (RV) thrombus attached to
the tricuspid valve, a hypertrophied left ventricle with an ejection
fraction of 25–30% (50% in 2017) and a globally hypokinetic left ven-
tricle (Figure 2A and Video 1). The apical four-chamber view showed a
3 cm elongated (type A) mobile structure attached to the tricuspid
valve and dilated RV (Figure 2B and C; Videos 2 and 3). Subsequent
computed tomography pulmonary angiogram (CTPA) revealed bilat-
eral pulmonary emboli with thrombotic material in all lobar arteries
(Figure 3A) and the right pulmonary artery (Figure 3B). Retrograde
opacification of the hepatic veins was present, indicating right
heart strain (Figure 3C). Computed tomography of the abdomen and
pelvis did not identify any evidence of visceral malignancy.
Carcinoembryonic antigen, alpha-fetoprotein, and carbohydrate anti-
gen 19-9 were all within a normal range.
Given his haemodynamic stability on admission, we decided not to
proceed with thrombolysis. Instead, he was promptly initiated on a
bridging regime of low-molecular-weight heparin (1 mg/kg twice
daily) and warfarin therapy. On Day 6, the previously seen mobile
structure was no longer visible (Figure 2D). Furosemide 40 mg once
daily was started on admission for his mild peripheral oedema.
Considering his severe left ventricular systolic dysfunction (LVSD),
spironolactone 12.5 mg once daily was started, and his bisoprolol
up-titrated to 7.5 mg once daily. The angiotensin receptor blocker,
initially held due to the acute kidney injury, was re-started after his
renal function returned to baseline with the aim of up-titration in the
future. Due to the patient’s improvement on anticoagulation, the ab-
sence of cardiac chest pain and specific ECG changes, coronary angi-
ography was cancelled and will instead be done after a follow-up
echocardiogram. Due to the widespread nature of the PE, the pres-
ence of RHTh, and the lack of any evidence of malignancy, haematol-
ogy was consulted. After discussion, the thrombophilia screen was
deemed unnecessary due to his recent immobility, AF, and congestive
.................................................................................................
Timeline Description
Four weeks Start of productive cough
Three weeks Patient recalls the start of mild pleuritic chest pain,




Patient presents to the Emergency Department with
worsening dyspnoea. Bedside trans-thoracic echo-
cardiogram (TTE) reveals a large mobile structure
3 cm in length, attached to the tricuspid valve.
Right ventricle is dilated with impaired function.
Left ventricular ejection fraction—25–30%
Computed tomography pulmonary angiogram shows
widespread bilateral pulmonary emboli
Therapeutic dose of enoxaparin and loop diuretics
started, angiotensin-converting enzyme inhibitor
held due to the mild acute kidney injury
Day 1 Warfarin therapy started with a bridging enoxaparin
therapy
Day 3 Computed tomography of the abdomen and pelvis
demonstrated no definite evidence of visceral
malignancy
Day 6 Repeated TTE shows no evidence of any mass on his
tricuspid valve or free-floating thrombus in his right
ventricle
Day 7 Spironolactone started
Day 8 Patient discharged with an INR of 3.1. General practi-
tioner to check INR in 1 week. Telephone follow-
up in 1 and 3 months. Outpatient echocardiogram
will assess the need for coronary angiography













































heart failure. Follow-up was performed at 1 and 3 months, where the
patient reported diminished breathlessness, resolved orthopnoea
and increased exercise tolerance.
Discussion
Whilst RHTh complicated by PE usually presents as an emergency,
this case provides evidence of subacute presentation further compli-
cated by new-onset AF and LVSD. Several important points emerge
from this case.
The subacute presentation complicated by new-onset AF and
LVSD highlights the difficulty in establishing the exact aetiology. The
preceding lower respiratory tract infection (LRTI) could have acted as
a trigger for new-onset AF. Being a prothrombotic state, AF, coupled
with reduced mobility from exertional breathlessness, may have pre-
cipitated a peripheral thrombus formation.6 The elongated shape of
the RHTh supports this, i.e. the thrombus dislodged from the periph-
ery and was captured in-transit by the tricuspid valve.3 Alternatively,
the LRTI could have contributed to venous stasis and blood pro-
coagulability and, in turn, increase his risk of peripheral venous
thromboembolism. The widespread PE could have subsequently trig-
gered the new-onset AF and, in turn, led to congestive cardiac failure,
although it is difficult to determine their temporal relations.7
Early trans-thoracic echocardiograms (TTEs) is a useful screening
test and should be considered in patients with suspected or con-
firmed PE to assess the right ventricular function and rule out RHTh,
whose presence can significantly change the management.8,9 Previous
reports suggest that RHTh might be identified in up to 4.5% of
patients.2,10 However, the true incidence is likely to be underre-
ported due to the low sensitivity of TTEs compared with trans-oe-
sophageal echocardiograms.1,11,12
Describing the specific shape of the RHTh can help estimate its origin
and the likelihood of causing PE. The mobile type A RHTh carries a high
risk of severe PE with an early (<_8days) mortality of 28–42%, compared
with a mortality rate of 2.5% in acute PE alone.1,3,13 In contrast, the less
mobile type B thrombus likely originates within the cardiac chambers, is
less likely to embolize and is thought to carry better outcomes.3
With no available guidelines, treatment of RHTh must be individual-
ized. The main treatment options are anticoagulation, systemic or
catheter-directed thrombolysis, and surgical or percutaneous embolec-
tomy.5 Thrombolysis has been described to have better outcomes than
anticoagulation alone or surgery,1 but a report of sudden near-
catastrophic embolization post-thrombolysis has been described.14
Thrombolysis should be particularly cautioned in type B thrombus in
fear of dissolving the stalk connecting the thrombus to the cardiac wall.4
In contrast, Barrios et al.15 showed no significant difference in mortality in
patients receiving anticoagulation therapy alone vs. anticoagulation with
reperfusion therapy. Only limited data are available on the time it takes
to dissolve RHTh. In this case, the mobile clot seen on admission was no
longer visible on Day 6. Therefore, the RHTh has either dissolved sec-
ondary to the anticoagulation therapy or embolized without causing any
further symptoms. Ferrari et al.16 reported the disappearance of RHTh
2h after thrombolysis in 50% of patients. For one patient on heparin infu-
sion, the clot disappeared on Day 6 with an improvement of RV haemo-
dynamics. Surgery is often the treatment of choice in very large RHTh
that is not amenable to thrombolysis or is complicated by structural
Figure 1 A 12-lead electrocardiogram showing atrial fibrillation with T-wave inversions in leads III, aVF, and in precordial leads V1, V2, V3, and V4.




heart defects.17 Percutaneous embolectomy offers a less invasive ap-
proach than surgery but carries a risk of cardiac tamponade, displacing
the thrombotic material and pulmonary haemorrhage.4
Lastly, this case raises a few interesting management dilemmas.
After prompt diagnosis and treatment of the RHTh with the bilateral
Figure 2 (A) Parasternal long axis of the heart demonstrating a right ventricular thrombus attached to the tricuspid valve and severe left ventricular
impairment; (B) Apical four-chamber view of the heart demonstrating a 3 cm long right ventricular thrombus attached to the tricuspid valve, enlarged
right ventricle with impairment and deviation of the interventricular septum towards the left ventricle; (C) Apical four-chamber view focused on the
right ventricle. This view shows a much clearer outline of the elongated tricuspid valve thrombus; (D) Day 6 after admission: Parasternal long-axis
view of the heart showing the disappearance of the right ventricular thrombus.
Video 1 Parasternal long axis of the heart demonstrating a right
ventricular thrombus attached to the tricuspid valve and severe left
ventricular impairment.
Video 2 Apical four-chamber view of the heart demonstrating a
3 cm long right ventricular thrombus attached to the tricuspid valve,
enlarged right ventricle with impairment and deviation of the inter-
ventricular septum towards the left ventricle.













PE, the severe LVSD, and new-onset AF must be addressed. Given
the patient’s previous history of mild coronary artery disease, we had
a low threshold for coronary angiography after his CTPA. However,
this was eventually cancelled due to the rapid improvement with anti-
coagulation, the absence of cardiac chest pain and specific ECG signs.
Furthermore, despite this being the patient’s first PE, his new-onset
AF with a CHA2DS2-VASc score of 6 requires lifelong anticoagula-
tion. In cases without AF, anticoagulation would be typically contin-
ued for a minimum of 3–6 months.18
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